Boardroom Alpha
Start trial
8-K primary document
CHRS · Current Report (Form 8-K) · Filed January 13, 2026

Coherus Oncology Inc — 8-K exhibit

chrs-20260113xex99d1.htm
Coherus Oncology Inc on Boardroom Alpha
Exhibit 99.1

GRAPHIC

©2026 Coherus Oncology, Inc. Coherus Oncology Value Proposition Shareholder Value Creation Focused on Drugs, Data and Deals 1 DRUGS DATA DEALS Tagmokitug anti-CCR8 cytolytic antibody Casdozokitug IL-27 antagonist Commercial Stage Clinical Stage Tagmokitug • HNSCC – Mid 2026 • GC, GEJ, EAC – Mid 2026 • CRC – H2 2026 • ESCC – H2 2026 • Additional indications starting in 2026 Casdozokitug • HCC – Mid 2026 Tagmokitug novel combinations Ex-US licensing LOQTORZI® US supply agreements NPC = Nasopharyngeal Carcinoma; HNSCC = Head and Neck Squamous Cell Carcinoma; GC = Gastric Cancer; GEJ = Gastro-esophageal-junction; EAC = Esophageal Adenocarcinoma; ESCC = Esophageal Squamous Cell Carcinoma; HCC = Hepatocellular Carcinoma; sqNSCLC = squamous Non-Small Cell Lung Cancer $172.1M* in cash, cash equivalents and investments at the end of Q4 2025, expected to support operations through end of 2026 * Cash, cash equivalents and investments as of December 31, 2025, inclusive of Transition Service Agreement (TSA)-related collections that will be applied to associated TSA payables and accrued liabilities. The preliminary fourth quarter and full year 2025 financial information presented herein has not been audited and is subject to change

GRAPHIC

©2025 Coherus ©2026 Coherus Oncology, Inc. 2 LOQTORZI® Delivering Steady Demand and Revenue Growth Projected to Reach $150-200M in Revenues by 2028 in $250M Market 2024 2025* 2028 19.1 ~40.8 150-200 0 50 100 150 Strong demand growth for LOQTORZI supported by data strength and commercial efforts Resulting in steady revenue growth, projected to ~$150-200 million by 2028 Q1 Q2 Q3 Q4* 7.3 10.0 11.2 ~12.3 LOQTORZI Annual Revenues (US$ M) 2025 Quarterly LOQTORZI Revenues (US$ M) Projected 10-15% QoQ growth LOQTORZI Demand Trend +16% +19% +12% +15% Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 2024 2025 * Q4 and full year 2025 financial information presented herein is preliminary and has not been audited and is subject to change

Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer